Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200 - Seite 2
About OCU200
OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related
Macular Degeneration (Wet-AMD). Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss as the disease progresses. The formation of
fragile and leaky new blood vessels leads to fluid accumulation in and around the retina, causing damage to vision.
OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin, that are already present normally in retinal tissues. OCU200 possesses unique features which enable it to (a) efficiently target leaky blood vessels, (b) regress the existing abnormal blood vessels, and (c) inhibit the growth of new blood vessels in the retina and choroid. Tumstatin, which acts as an anti-VEGF, anti-inflammatory and anti-oxidative agent, is the active component of OCU200. It binds to integrin receptors, which play a crucial role in disease pathogenesis. Transferrin facilitates the targeted delivery of tumstatin into the retina and choroid and potentially helps increase the interaction between tumstatin and integrin receptors.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy
platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved
diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.
Lesen Sie auch
About Kemwell Biopharma Pvt. Ltd.
Kemwell is a leading biologics CDMO in Asia which provides services to global biopharmaceutical organizations for both clinical and commercial needs. Kemwell, located in Bangalore, India provides
customers with high quality and cost-effective access to state-of-the-art technology for development and manufacturing of all mammalian cell culture-based products. Kemwell’s facilities consists of
cGMP drug substance manufacturing suites with over 4500L bioreactor capacity, sterile fill and finish line for cGMP drug product manufacturing and development laboratories to support process and
analytical development and production of protein therapeutics such as monoclonal antibodies, bi-specific antibodies and fusion proteins. For more information, please visit www.kemwellbiopharma.com.